Skip to content
Peptide Atlas
All peptides

Semaglutide

Tier 1 · Human trials
Also known as Ozempic · Wegovy · Rybelsus

Supported by extensive Tier 1 human randomized controlled trial data, including the SUSTAIN, PIONEER, STEP, ESSENCE, and cardiovascular outcome trials, plus regulatory (FDA) approvals. Some ancillary claims rest on animal (cardiotoxicity, thyroid C-cell tumors), observational, expert-opinion, or anecdotal ('Ozempic face') evidence, and certain indications (MASH) are recent and single-source.

Half-life
~168 h
Routes
Subcutaneous injection · Oral
Goals
fat loss · body composition
Cost / mg
Not recorded

How it works

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural gut hormone GLP-1. It tells the pancreas to release more insulin and less glucagon, but only when blood sugar is elevated, which lowers blood glucose with a low risk of hypoglycemia. It also acts on appetite regulation and slows the rate at which the stomach empties, leading to reduced food intake and weight loss.

Overview

Overview

Semaglutide (marketed as Ozempic, Wegovy, and Rybelsus) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a modified human GLP-1 analogue sharing 94% amino acid sequence homology with native GLP-1, engineered with three structural modifications (using Novo Nordisk's proprietary protein-acylation technology) that make it resistant to DPP-4 degradation and extend its half-life to roughly one week.

Mechanism

By agonizing the GLP-1 receptor, semaglutide stimulates insulin secretion and inhibits glucagon release in a blood-glucose-dependent manner—improving glycemic control while keeping hypoglycemia risk low. It also regulates appetite and delays gastric emptying, promoting reduced food intake and weight loss. Semaglutide is notable as the only GLP-1RA available in both subcutaneous and oral formulations; the oral form (Rybelsus) is co-formulated with the absorption enhancer SNAC to enable transcellular absorption across the gastric mucosa, and was the first approved oral GLP-1 receptor agonist for type 2 diabetes.

Approved Uses

First approved in the U.S. in 2017, semaglutide is FDA-approved across three brand-name products:

  • Rybelsus (oral) and Ozempic (injection): adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is used as a second-line option for glycemic control.
  • Ozempic: reducing the risk of major adverse cardiovascular events (cardiovascular death, nonfatal MI, or nonfatal stroke) in patients with established cardiovascular disease. Sources differ on whether this indication requires type 2 diabetes — see the points of contention below.
  • Wegovy: chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related comorbidity (e.g., hypertension, T2DM, dyslipidemia); weight reduction and maintenance in adults and pediatric patients aged 12+ with obesity; reduction of major adverse cardiovascular event risk in adults with established CV disease and obesity/overweight; and (accelerated approval, August 2025) noncirrhotic MASH with moderate-to-advanced liver fibrosis (stages F2–F3). Only the Wegovy formulation is FDA-approved specifically for weight loss.

Clinical Evidence

The SUSTAIN and PIONEER trials (1.0 mg once-weekly subcutaneous and oral semaglutide) demonstrated statistically significant HbA1c reductions of 1.5–1.9% over 30–56 weeks in T2DM, with 5–10% weight reduction from baseline. The STEP program studied 2.4 mg once-weekly subcutaneous semaglutide in obesity. In an East Asian obesity trial, 2.4 mg produced a mean bodyweight reduction of −13.2% and 1.7 mg −9.6% at week 68 (versus −2.1% for placebo), with 83% and 72% of subjects respectively achieving ≥5% weight loss, and abdominal visceral fat reduced by 40.0% and 22.2%. In a cardiovascular outcomes trial of 17,604 adults with preexisting CV disease and overweight/obesity without diabetes, semaglutide reduced major adverse cardiovascular events by 20%; weight loss was sustained up to 4 years (−10.2% vs −1.5% placebo at 208 weeks). In the ESSENCE trial, 72 weeks of 2.4 mg/week resolved MASH without worsening fibrosis in 62.9% (vs 34.3% placebo) and achieved fibrosis improvement in 36.8% (vs 22.4%).

Investigational / Off-label

A mouse-model study suggests semaglutide may reduce doxorubicin-induced cardiotoxicity via the PI3K/AKT pathway and reduced mitochondrial BNIP3 expression—this is animal/in-vitro data only. GLP-1 receptor agonists are used off-label for weight loss; current evidence does not support their use for eating disorder symptoms, and they could potentially worsen or improve ED pathology.

Pharmacokinetics

Semaglutide has a predictable PK profile with a ~1-week half-life, reaching steady state in 4–5 weeks. Over 99% is albumin-bound; it is metabolized by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, with metabolites excreted in urine and feces. Clearance (~0.0348 L/h) and total volume of distribution (~7.7 L) scale approximately with body weight, with low interindividual variability (~15%). AUC and Cmax increase dose-proportionally. Oral bioavailability is only ~0.8% under recommended fasting conditions and is highly variable within subjects (137%), which the long half-life buffers to ~33% variability in steady-state exposure. Post-dose fasting time and water volume are key covariates for oral exposure. Only minor PK differences exist between healthy subjects and those with T2DM.

What the research shows

231 findings extracted from the 31 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 39 human trial findings, 6 human study findings, 1 animal finding and 7 expert opinion findings.

  • human trialThere was no significant difference in oral bioavailability of semaglutide in healthy subjects and subjects with type 2 diabetes2

  • human trialSignificant reductions in glycated haemoglobin and body weight have been shown with oral semaglutide compared with placebo and several anti-diabetic agents3

  • human trialSemaglutide has resulted in a 1.5-1.9% glycosylated hemoglobin A1c reduction after 30-56 weeks8

  • human trialSemaglutide produced 5-10% weight reduction from baseline in clinical efficacy studies8

  • human trialData were obtained from trials with subcutaneous and intravenous administration of semaglutide using frequent PK sampling with a total of 353 subjects and 10,573 concentration values9

  • human trialSemaglutide demonstrated efficacy in dose response studies and main clinical trials for glycemic control in type 2 diabetes10

  • human trialRybelsus® tablet demonstrates efficacy in improving glycemic control in patients with type 2 diabetes mellitus (T2DM)11

  • human trialOzempic® injectable provides indication of reducing the risk of major adverse cardiovascular events in patients with and without T2DM11

Show the remaining 45

  • human trialSUSTAIN clinical trials demonstrated statistically significant reductions in HbA1c with semaglutide in patients with T2DM11

  • human trialCardiovascular outcome trials established that semaglutide can reduce various cardiovascular risk factors in patients with established cardiovascular disorders12

  • human trialThe pharmacokinetics, safety and tolerability of OW s.c. semaglutide in healthy Chinese subjects were consistent with previous clinical pharmacology trials of OW s.c. semaglutide in other populations13

  • human trialOW s.c. semaglutide provided good glycaemic control versus a wide range of comparators, in addition to providing additional clinical benefits such as weight loss, cardiovascular risk reduction and lowering of systolic blood pressure, with a low risk of hypoglycaemia13

  • human trialClinical efficacy and safety were evaluated in main clinical studies14

  • human trialWegovy formulation (semaglutide) received accelerated FDA approval in August 2025 for treating MASH with moderate-to-advanced fibrosis (F2-F3)15

  • human trial72 weeks of 2.4 mg/week subcutaneous injection resulted in resolution of MASH without worsening of fibrosis in 62.9% vs. 34.3% placebo (p <0.001)15

  • human trial72 weeks of 2.4 mg/week subcutaneous injection resulted in ≥1 stage reduction in liver fibrosis without worsening of MASH in 36.8% vs. 22.4% placebo (p <0.001)15

  • human trialReductions from baseline to 72 weeks suggest significant improvement in MASH resolution with ALT ≥17 U/L or ≥20% and fibrosis improvement (VCTE LSM ≥30%; MRE LSM ≥20%; ELF ≥0.5)15

  • human trialSemaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes20

  • human trialWeight loss continued over 65 weeks and was sustained for up to 4 years20

  • human trialAt 208 weeks, semaglutide was associated with mean reduction in weight of -10.2% versus placebo -1.5%20

  • human trialAt 208 weeks, semaglutide was associated with waist circumference reduction of -7.7 cm versus placebo -1.3 cm20

  • human trialAt 208 weeks, semaglutide was associated with waist-to-height ratio reduction of -6.9% versus placebo -1.0%20

  • human trialClinical trials have shown effectiveness of semaglutide in reducing body weight and improving metabolic parameters22

  • human trialSemaglutide 2.4 mg once weekly produces estimated mean bodyweight reduction of -13.2% from baseline to week 68 in adults from east Asia with obesity23

  • human trialSemaglutide 1.7 mg once weekly produces estimated mean bodyweight reduction of -9.6% from baseline to week 68 in adults from east Asia with obesity23

  • human trialPlacebo produces estimated mean bodyweight reduction of -2.1% from baseline to week 6823

  • human trialSemaglutide 2.4 mg achieves treatment difference of -11.1 percentage points (95% CI -12.9 to -9.2) versus placebo for bodyweight reduction23

  • human trialSemaglutide 1.7 mg achieves treatment difference of -7.5 percentage points (95% CI -9.6 to -5.4) versus placebo for bodyweight reduction23

  • human trial83% of participants in semaglutide 2.4 mg group achieved 5% or higher reduction in baseline bodyweight at week 6823

  • human trial72% of participants in semaglutide 1.7 mg group achieved 5% or higher reduction in baseline bodyweight at week 6823

  • human trial21% of participants in placebo group achieved 5% or higher reduction in baseline bodyweight at week 6823

  • human trialAbdominal visceral fat area reduced by 40.0% in semaglutide 2.4 mg group versus 6.9% in placebo group23

  • human trialAbdominal visceral fat area reduced by 22.2% in semaglutide 1.7 mg group versus 6.9% in placebo group23

  • human trialGlucagon-like peptide-1 (GLP-1) receptor agonists have shown promise in encouraging glycemic control and promoting weight loss in patients with or without type 2 diabetes24

  • human trialAll three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction24

  • human trialFood and Drug Administration approval of Wegovy (semaglutide) for weight loss was granted following trial results24

  • human trialGLP-1RAs effectively improve glycemic control and cause weight loss25

  • human trialSemaglutide has a potent glucose-lowering effect25

  • human trialSemaglutide has an overall favorable risk/benefit profile for patients with type 2 diabetes25

  • human studySemaglutide has been approved as a second line treatment option for better glycaemic control in type 2 diabetes12

  • human studyResults of semaglutide for the treatment of type II diabetes have been overwhelmingly positive16

  • human studySemaglutide has effects on appetite suppression and weight loss16

  • human studyRybelsus® tablet demonstrates efficacy in improving glycemic control in patients with type 2 diabetes mellitus (T2DM)17

  • human studyOzempic® injectable brand provides an indication of reducing the risk of major adverse cardiovascular events in patients with and without T2DM17

  • human studyOzempic® injection is approved for reducing the risk of major adverse cardiovascular events, such as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients with and without T2DM and established cardiovascular disease17

  • animalSemaglutide significantly ameliorated doxorubicin-induced cardiac dysfunction27

  • expert opinionWegovy carries FDA approval for chronic weight management in patients with BMI 27 kg/m² or greater and at least one weight-related condition (eg, hypertension, type 2 diabetes, cholesterol) or in patients with a BMI 30 kg/m² or greater21

  • expert opinionOther semaglutide formulations are not FDA approved for weight loss21

  • expert opinionSemaglutide lowers body weight26

  • expert opinionOnce-weekly subcutaneous semaglutide has been approved in the US, Puerto Rico and Canada26

  • expert opinionSemaglutide has received a positive opinion in the EU for the treatment of patients with type 2 diabetes26

  • expert opinionPreliminary research on the use of GLP-1As to treat binge eating has been conducted; however, studies have design limitations and additional research is needed30

  • expert opinionAt the current time there is not sufficient evidence to support the use of GLP-1s to treat ED symptoms30

How it works

Based on 9 human trial findings, 4 animal findings, 1 in vitro finding, 6 expert opinion findings and 1 theoretical finding.

  • human trialA two-compartment pharmacokinetic model based on subcutaneous and intravenous semaglutide was extended to include data from six oral semaglutide trials conducted in either healthy volunteers or subjects with renal or hepatic impairment2

  • human trialOral semaglutide is co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, which facilitates the transcellular absorption of semaglutide across the gastric mucosa3

  • human trialSemaglutide can delay gastric emptying and may impact the absorption of oral medications8

  • human trialSemaglutide is a receptor agonist of the naturally occurring peptide hormone glucagon-like peptide-1 (GLP-1)9

  • human trialSemaglutide acts to stimulate insulin secretion and inhibit glucagon release depending on the blood glucose concentration, leading to improved blood glucose levels together with a reduced risk of hypoglycaemia9

  • human trialSemaglutide has 94% amino acid sequence homology to native GLP-19

  • human trialSemaglutide has three structural modifications that make it less susceptible to degradation by dipeptidyl peptidase-4 (DPP-4) enzymes9

  • human trialSemaglutide is a GLP-1 receptor agonist14

Show the remaining 13

  • human trialSemaglutide-based medications belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class and mimic the action of GLP-1, regulating appetite and promoting weight loss22

  • animalBnip3 is the candidate gene that impaired the protective effect of semaglutide in doxorubicin-induced cardiotoxicity27

  • animalOverexpression of BNIP3 prevented the improvement in cardiac function caused by semaglutide27

  • animalSemaglutide ameliorates doxorubicin-induced mitochondrial and cardiac dysfunction via PI3K/AKT pathway by reducing BNIP3 expression in mitochondria27

  • animalImprovement in mitochondrial function reduces doxorubicin-mediated cardiac injury and improves cardiac function27

  • in vitroSemaglutide via PI3K/AKT pathway reduced BNIP3 expression in the mitochondria, improving mitochondrial function27

  • expert opinionSemaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist17

  • expert opinionSemaglutide is a glucagon-like-peptide 1 (GLP-1) agonist21

  • expert opinionSemaglutide is a new GLP-1 homolog24

  • expert opinionSemaglutide is a modified human glucagon-like peptide-1 (GLP-1) analogue26

  • expert opinionSemaglutide lowers blood glucose by stimulating the release of insulin26

  • expert opinionSemaglutide was developed using Novo Nordisk's proprietary protein-acylation technology26

  • theoreticalWEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist7

Dosing

Based on 12 human trial findings, 2 human study findings and 6 expert opinion findings.

  • human trialAdminister WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals6

  • human trialInject subcutaneously in the abdomen, thigh, or upper arm6

  • human trialInitiate at 0.25 mg once weekly for 4 weeks, then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage6

  • human trialFor patients with MASH, the maintenance dosage of WEGOVY is 2.4 mg once weekly, or can be decreased to 1.7 mg once weekly if not tolerated6

  • human trialFor all other indications except MASH treatment, the maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly6

  • human trialSemaglutide is appropriate for once-weekly administration9

  • human trialWegovy® is approved for adults with obesity defined by initial BMI of 30 kg/m² or higher11

  • human trialWegovy® is approved for overweight individuals with BMI of 27 kg/m² or higher with at least one weight-related comorbid condition11

Show the remaining 12

  • human trialNo dose adjustment is necessary for semaglutide in Chinese patients with T2D13

  • human trialThe medication is administered by subcutaneous injection14

  • human trialSUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide on participants with type 2 diabetes24

  • human trialSTEP trial examined the effects of 2.4 mg, once-weekly, subcutaneous semaglutide on patients with obesity24

  • human studyNo dosing adjustments needed in patients with upper gastrointestinal disease, renal impairment or hepatic impairment4

  • human studyNo dosing adjustments needed in patients with upper gastrointestinal disease, renal impairment or hepatic impairment19

  • expert opinionAdminister WEGOVY injection once weekly as an adjunct to diet and increased physical activity7

  • expert opinionInject subcutaneously in the abdomen, thigh, or upper arm7

  • expert opinionInitiate at 0.25 mg once weekly for 4 weeks7

  • expert opinionPatient selection for semaglutide should target those with MASH with stage 2-3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8-15 kPa), MRE (3.1-4.4 kPa), or ELF (9.2-10.5)15

  • expert opinionWegovy® injection is used in combination with a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity defined by an initial BMI of 30 kg/m² or higher17

  • expert opinionSemaglutide is administered using an injection device as a subcutaneous formulation26

How the body handles it

Based on 32 human trial findings and 13 human study findings.

  • human trialSemaglutide at a dose of 0.5 or 1 mg has a half-life of 7 days1

  • human trialSemaglutide would reach steady state in 4–5 weeks1

  • human trialPost-dose fasting time, co-ingestion of a large water volume, and body weight were the most important covariates affecting semaglutide exposure2

  • human trialBioavailability was 0.8% when oral semaglutide was dosed using the recommended dosing conditions (30 min post-dose fasting time, administered with ≤ 120 mL of water)2

  • human trialBioavailability increases with longer post-dose fasting time and decreases with higher water volume2

  • human trialWithin-subject variability in bioavailability was 137%2

  • human trialWith once-daily dosing and a long half-life, within-subject variability in steady-state exposure translates into 33%2

  • human trialBioavailability was 0.8% when oral semaglutide was dosed using the recommended dosing conditions (30 min post-dose fasting time, administered with ≤ 120 mL of water)3

Show the remaining 37

  • human trialPost-dose fasting time, co-ingestion of a large water volume, and body weight were the most important covariates affecting semaglutide exposure3

  • human trialWithin-subject variability in bioavailability was 137%, which with once-daily dosing and a long half-life translates into 33% within-subject variability in steady-state exposure3

  • human trialThere was no significant difference in oral bioavailability of semaglutide in healthy subjects and subjects with type 2 diabetes3

  • human trialAs a dose of 0.5 or 1 mg, semaglutide has a half-life of 7 days8

  • human trialSemaglutide would reach steady state in 4-5 weeks8

  • human trialSemaglutide half-life is approximately 1 week9

  • human trialThe prolonged exposure of semaglutide is mainly driven by slow systemic elimination and, to a lesser extent, by delayed absorption9

  • human trialMore than 99% of semaglutide is bound to plasma albumin9

  • human trialSemaglutide is metabolised by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain9

  • human trialSemaglutide metabolites are primarily excreted in the urine and faeces9

  • human trialFor a typical subject with type 2 diabetes, clearance was estimated to be 0.0348 L/h9

  • human trialCentral volume of distribution estimated to be 3.59 L for a typical subject with type 2 diabetes9

  • human trialPeripheral volume of distribution estimated to be 4.10 L for a typical subject with type 2 diabetes9

  • human trialTotal volume of distribution of 7.7 L for a typical subject with type 2 diabetes9

  • human trialInterindividual variation was low (~15%) for both clearance and volumes of distribution9

  • human trialResidual error was low (<5%)9

  • human trialClearance and total volume of distribution were approximately proportional to body weight9

  • human trialMinor differences were identified between healthy subjects and subjects with type 2 diabetes with respect to clearance and absorption rate9

  • human trialMinor differences were identified between injection sites with respect to bioavailability9

  • human trialSemaglutide has defined pharmacokinetic and pharmacodynamic properties that support its clinical use10

  • human trialSemaglutide undergoes absorption, distribution, metabolism, and excretion (ADME)10

  • human trialThe steady-state exposure of semaglutide was higher for subjects treated with 1.0 mg semaglutide compared to 0.5 mg semaglutide13

  • human trialThe total exposure of semaglutide increased in a dose-proportional manner in healthy Chinese subjects13

  • human trialClinical pharmacology includes both pharmacokinetics and pharmacodynamics assessments14

  • human studySemaglutide has a predictable pharmacokinetic profile with a long half-life that allows for once-weekly subcutaneous administration4

  • human studyThe AUC and Cmax of both oral and subcutaneous semaglutide increased with dose4

  • human studyFood and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure4

  • human studyBody weight may affect semaglutide exposure, but further studies are needed to confirm this4

  • human studySemaglutide has a predictable pharmacokinetic profile with a long t1/2 that allows for once-weekly subcutaneous administration5

  • human studyThe AUC and Cmax of both oral and subcutaneous semaglutide increased with dose5

  • human studyFood and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure5

  • human studyBody weight may affect semaglutide exposure, but further studies are needed to confirm this5

  • human studyThe pharmacokinetic parameters included area under the curve plasma concentrations (AUC), maximal plasma concentration (Cmax), time to Cmax, half-life (t1/2), and clearance5

  • human studySemaglutide has a predictable pharmacokinetic profile with a long half-life that allows for once-weekly subcutaneous administration19

  • human studyThe AUC and Cmax of both oral and subcutaneous semaglutide increased with dose19

  • human studyFood and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure19

  • human studyBody weight may affect semaglutide exposure, but further studies are needed to confirm this19

Safety and side effects

Based on 38 human trial findings, 8 human study findings, 2 animal findings, 6 expert opinion findings and 1 anecdotal finding.

  • human trialThere are few drug interactions with semaglutide1

  • human trialOral semaglutide has been demonstrated to be well tolerated3

  • human trialWEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)6

  • human trialAcute gallbladder disease has occurred in clinical trials6

  • human trialConcomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia6

  • human trialThere are few drug interactions and dose adjustments are not necessary8

  • human trialClinical safety data were collected across multiple trials with analysis of adverse events10

  • human trialTreatment with OW s.c. semaglutide was well tolerated in healthy Chinese subjects13

Show the remaining 47

  • human trialThe most common adverse events were gastrointestinal, and no new safety signals were identified13

  • human trialSafety profile includes assessment of adverse events and serious adverse events14

  • human trialSemaglutide showed a favorable hepatic safety profile in the ESSENCE trial, with no discontinuations due to liver enzyme elevations15

  • human trialThe most common adverse events were gastrointestinal (nausea, diarrhea, constipation, vomiting), generally mild and transient15

  • human trialIncidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk18

  • human trialNausea occurred in 2.05% to 19.95% of semaglutide-treated patients18

  • human trialDiarrhea occurred in 1.4% to 13% of semaglutide-treated patients18

  • human trialNasopharyngitis had mean prevalence of 8.23% in semaglutide-treated patients18

  • human trialVomiting had mean prevalence of 5.97% in semaglutide-treated patients18

  • human trialIncreased lipase levels occurred with mean of 6.5% in semaglutide-treated patients18

  • human trialHeadaches had mean prevalence of 7.92% in semaglutide-treated patients18

  • human trialDecreased appetite was reported consistently at 7% in semaglutide-treated patients18

  • human trialInfluenza symptoms had mean prevalence of 5.23% in semaglutide-treated patients18

  • human trialDyspepsia had mean prevalence of 5.18% in semaglutide-treated patients18

  • human trialConstipation had mean prevalence of 6.91% in semaglutide-treated patients18

  • human trialSerious adverse events varied from 7% to 25.2% across studies18

  • human trialSemaglutide was associated with fewer serious adverse events across all BMI categories20

  • human trialSemaglutide was associated with increased rates of trial product discontinuation20

  • human trialDiscontinuations increased as BMI class decreased20

  • human trialSemaglutide causes gastrointestinal side effects including delayed gastric emptying22

  • human trialGastrointestinal disorders reported in 59% of participants in semaglutide 2.4 mg group, mostly mild to moderate in severity23

  • human trialGastrointestinal disorders reported in 64% of participants in semaglutide 1.7 mg group23

  • human trialGastrointestinal disorders reported in 30% of participants in placebo group23

  • human trialAdverse events leading to trial product discontinuation occurred in 3% of semaglutide 2.4 mg group and 3% of semaglutide 1.7 mg group versus 1% in placebo group23

  • human trialSemaglutide induces mostly mild-to-moderate and transient gastrointestinal disturbances25

  • human trialSemaglutide increases the risk of biliary disease (cholelithiasis)25

  • human trialNo unexpected safety issues have arisen to date with semaglutide25

  • human trialThe established safety profile for semaglutide is similar to that of other GLP-1RAs25

  • human trialDefinitive conclusions for pancreatic and thyroid cancer cannot be drawn at this point due to low incidence of these conditions25

  • human trialPatients at risk for deterioration of existing diabetic retinopathy should be carefully monitored if treated with semaglutide, particularly if also treated with insulin25

  • human studyThere are limited drug-drug interactions4

  • human studyThere are limited drug–drug interactions and no dosing adjustments in patients with upper gastrointestinal disease, renal impairment or hepatic impairment5

  • human studyAcute pancreatitis has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY6

  • human studySemaglutide has been proved to be safe in adults and elderly patients with renal or hepatic disorders demanding no dose modification12

  • human studySemaglutide is well tolerated with no risk of hypoglycaemia in monotherapy12

  • human studySemaglutide suffers from gastrointestinal adverse effects12

  • human studyThere are limited drug-drug interactions19

  • human studyRapid weight and fat loss with Ozempic can lead to 'Ozempic face,' where facial volume and fat are depleted, resulting in wrinkles and sagging skin22

  • animalIn rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures6

  • animalIn rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures7

  • expert opinionIt is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined6

  • expert opinionIt is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans7

  • expert opinionClinicians should monitor for rare but serious risks, including acute kidney injury (from dehydration), symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and lean mass loss15

  • expert opinionDiscontinuation of Ozempic should be considered prior to general anesthesia due to gastrointestinal side effects22

  • expert opinionIt is possible that GLP-1As could exacerbate, or contribute to the development of, ED pathology and negatively impact ED treatment30

  • expert opinionIt is possible that GLP-1As could maintain, worsen, or improve ED symptoms30

  • anecdotal'Ozempic face' describes rapid facial weight loss leaving a distorted facial appearance as a purported side effect21

What people use it for

Based on 22 human trial findings, 2 human study findings, 1 animal finding and 11 expert opinion findings.

  • human trialOral semaglutide is the first oral glucagon-like peptide-1 receptor agonist for treating type 2 diabetes2

  • human trialOral semaglutide is the first oral glucagon-like peptide-1 receptor agonist for treating type 2 diabetes3

  • human trialWEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight6

  • human trialWEGOVY is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity6

  • human trialWEGOVY is indicated for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2 to F3) in adults under accelerated approval6

  • human trialWEGOVY injection is indicated to reduce the risk of major adverse cardiovascular events in adults with established CV disease and either obesity or overweight7

  • human trialWEGOVY injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity7

  • human trialWEGOVY injection is indicated for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis7

Show the remaining 28

  • human trialWEGOVY tablets are indicated to reduce the risk of major adverse CV events in adults with established CV disease and either obesity or overweight7

  • human trialWEGOVY tablets are indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity7

  • human trialSemaglutide is a glucagon-like peptide-1 receptor agonist approved for clinical use in the management of type 2 diabetes mellitus8

  • human trialSemaglutide has a potential role among patients who require weight loss with a low risk of hypoglycemia8

  • human trialSemaglutide is approved for the treatment of type 2 diabetes mellitus, using the subcutaneous route of administration9

  • human trialSemaglutide is indicated for the treatment of type 2 diabetes mellitus10

  • human trialWegovy® injection is used for promoting weight loss in individuals dealing with obesity and overweight11

  • human trialWegovy® is approved for pediatric patients aged 12 and older with initial BMI at or above the 95th percentile for their age and sex11

  • human trialOnce-weekly subcutaneous semaglutide is an injectable glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes13

  • human trialSemaglutide is indicated for weight management under the brand name Wegovy14

  • human trialSemaglutide is used for management of diabetes and obesity18

  • human trialOzempic is Food and Drug Administration-approved for diabetes22

  • human trialSemaglutide 2.4 mg once weekly represents a promising treatment option for weight management in adults from east Asia with obesity, with or without type 2 diabetes23

  • human trialSemaglutide is the most recently approved GLP-1RA and the only GLP-1RA currently available as both subcutaneous and oral formulation25

  • human studySemaglutide is a glucagon like peptide-1 (GLP-1) receptor agonist available as monotherapy in both subcutaneous as well as oral dosage form12

  • human studySemaglutide is the first approved oral GLP-1 receptor agonist12

  • animalSemaglutide is a potential therapy to reduce doxorubicin-induced acute cardiotoxicity27

  • expert opinionSemaglutide is currently under scrutiny for anti-obesity purpose12

  • expert opinionCombination use of resmetirom with semaglutide 2.4mg/week has not been studied15

  • expert opinionSemaglutide is a glucagon-like peptide-1 receptor agonist used most commonly to treat type II diabetes16

  • expert opinionSemaglutide is approved by the US FDA as 3 separate brand name medications: Ozempic®, Wegovy®, and Rybelsus®17

  • expert opinionRybelsus® tablets are approved as an adjunct to diet and exercise for enhancing glycemic control in adults with T2DM17

  • expert opinionOzempic® injection is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM17

  • expert opinionWegovy® injection is approved for promoting weight loss in individuals dealing with obesity and overweight17

  • expert opinionWegovy® injection is approved for those who are overweight with a BMI of 27 kg/m² or higher in the presence of at least a weight-related comorbid condition such as hypertension, T2DM, or dyslipidemia17

  • expert opinionSemaglutide is under regulatory review in Japan and Switzerland for the treatment of type 2 diabetes26

  • expert opinionClinical development for obesity, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease is underway worldwide26

  • expert opinionGlucagon-like peptide-1 receptor agonists (GLP-1As) are being used as approved or off-label treatments for weight loss30

Other findings

Based on 1 human trial finding.

  • human trialSemaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA as 3 separate brand name medications: Ozempic®, Wegovy®, and Rybelsus®11

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Cancer risk for thyroid and pancreatic cancer remains unresolved.

Rodent studies show semaglutide causes thyroid C-cell tumors, and human relevance has not been determined (Label: WEGOVY- semaglutide injection, solution, HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. (5.1, 13.1) WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors. (4, 5.1) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙RECENT MAJOR CHANGES∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Indications and Usage (1) 08/2025 Dosage and Administration, Recommended Dosage Initiation and Escalation Schedule, Recommended Maintenance Dosage (2.2, 2.3) 08/2025 Warnings and Precaution, Acute Kidney Injury Due to Volume Depletion (5.5) 08/2025 Warning and Precautions, Severe Gastrointestinal Adverse Reactions, Pulmonary Aspiration During General Anesthesia or Deep Sedation (5.6, 5.11) 11/2024 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙INDICATIONS AND USAGE∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. (1) to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity. Adults with overweight in the presence of at least one weight related comorbid condition. (1) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. (1) The indication for MASH is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. (1) Limitations of Use Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. (1) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙DOSAGE AND ADMINISTRATION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals. (2.1) Inject subcutaneously in the abdomen, thigh, or upper arm. (2.1) In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment. (2.1) Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage. (2.2) For patients with MASH, the maintenance dosage of WEGOVY is 2.4 mg once weekly. If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly. (2.3) For all other indications except for MASH treatment, the maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly. (2.3)). Human data suggest thyroid cancer incidence <1% with no significant risk (Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.), but reviews state definitive conclusions for pancreatic and thyroid cancer cannot be drawn due to low incidence of these conditions (Safety of Semaglutide.). Wegovy remains contraindicated in patients with personal/family history of MTC or MEN 2 (HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. (5.1, 13.1) WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors. (4, 5.1) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙RECENT MAJOR CHANGES∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Indications and Usage (1) 08/2025 Dosage and Administration, Recommended Dosage Initiation and Escalation Schedule, Recommended Maintenance Dosage (2.2, 2.3) 08/2025 Warnings and Precaution, Acute Kidney Injury Due to Volume Depletion (5.5) 08/2025 Warning and Precautions, Severe Gastrointestinal Adverse Reactions, Pulmonary Aspiration During General Anesthesia or Deep Sedation (5.6, 5.11) 11/2024 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙INDICATIONS AND USAGE∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. (1) to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity. Adults with overweight in the presence of at least one weight related comorbid condition. (1) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. (1) The indication for MASH is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. (1) Limitations of Use Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. (1) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙DOSAGE AND ADMINISTRATION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals. (2.1) Inject subcutaneously in the abdomen, thigh, or upper arm. (2.1) In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment. (2.1) Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage. (2.2) For patients with MASH, the maintenance dosage of WEGOVY is 2.4 mg once weekly. If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly. (2.3) For all other indications except for MASH treatment, the maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly. (2.3)).

Limited evidence

Body weight effect on drug exposure not fully confirmed.

Multiple pharmacokinetic reviews note body weight may affect semaglutide exposure but further studies are needed to confirm this.

Limited evidence

Cardiotoxicity benefit is animal/in-vitro only.

The finding that semaglutide reduces doxorubicin-induced cardiotoxicity via PI3K/AKT and BNIP3 comes from C57/BL6J mouse models and in-vitro work (Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction.), not human trials.

Limited evidence

Insufficient evidence for eating disorder use, with possible harm.

A tier-3 review notes preliminary research on GLP-1As for binge eating has design limitations, there is not sufficient evidence to support use for ED symptoms, and GLP-1As could potentially exacerbate or worsen ED pathology.

Single source

MASH approval and combination data are recent and limited.

The MASH indication (accelerated FDA approval August 2025) and ESSENCE trial data are described by a single 2025 review; combination use of resmetirom with semaglutide 2.4 mg/week has not been studied.

Single source

'Ozempic face' is an anecdotal/observational side effect.

The 'Ozempic face' phenomenon (facial volume/fat depletion causing wrinkles and sagging) is described as a purported/anecdotal side effect rather than established from controlled trials.

What you may have heard

The 'no hypoglycemia risk' statement applies only to semaglutide used alone; combined with insulin or an insulin secretagogue it can cause hypoglycemia.

The review "Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes" describes semaglutide as well tolerated with no risk of hypoglycaemia specifically in monotherapy. That qualifier matters: the WEGOVY prescribing information warns that concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia, and may require reducing the dose of those agents. So the absence of hypoglycemia risk is a statement about monotherapy, not a general property of the drug in every regimen.

Inconsistency

Sources disagree on whether Ozempic's cardiovascular indication requires type 2 diabetes

A widely used clinical reference (StatPearls) describes the Ozempic brand as carrying a cardiovascular-risk-reduction indication in patients with and without type 2 diabetes. The Wegovy prescribing information is the label that carries a cardiovascular indication for people without diabetes — adults with established cardiovascular disease and either obesity or overweight. The two semaglutide products have different approved populations, so a summary that treats the brands together can misstate which patients an indication covers.

Other

Only Wegovy subcutaneous titration (0.25–2.4 mg) is given; the Rybelsus oral dose regimen (3/7/14 mg once daily) is not …

The profile emphasizes the oral route and its unusual fasting/water conditions but never states the actual oral doses, so a reader could erroneously apply the SC mg values to the oral tablet, which are pharmacologically non-equivalent.

What you may have heard

Two safety reviews read the same low thyroid-cancer rate in opposite ways.

Both reviews rest on the same observation: thyroid cancer appeared in fewer than 1% of semaglutide-treated patients. From this, the 'Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity' review concludes there is 'no significant risk' and even describes the data as 'excluding the hypothesis of carcinogenesis.' The 'Safety of Semaglutide' review draws the opposite methodological lesson from the same rarity, stating that definitive conclusions about thyroid (and pancreatic) cancer cannot be drawn precisely because the incidence of these conditions is so low. A rate too low to confirm harm is not the same as a rate low enough to rule it out.

Contested

Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglyc…

The statement claims 'in monotherapy there is no risk of hypoglycaemia,' which is directly supported by the second source stating 'Semaglutide is well tolerated with no risk of hypoglycaemia in monotherapy.' However, the statement also claims 'Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia,' which is supported by the first source. The two parts of the statement are not contradicted individually, but when combined they present a complete picture. Upon careful review, the first source explicitly states 'Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia' and the second source states 'Semaglutide is well tolerated with no risk of hypoglycaemia in monotherapy.' Both parts of the statement are actually supported by the sources, not contradicted. The statement is fully supported.

Contested

Semaglutide's clinical results for type II diabetes are described as strongly positive, yet its reception has been mixed rather than uniformly favorable.

The ethics review 'The Ethics of Ozempic and Wegovy' reports that results of semaglutide for treating type II diabetes have been 'overwhelmingly positive' and that the drug suppresses appetite and produces weight loss, which drove its popularity as a weight-loss treatment. At the same time, it notes that both governmental and popular reception to the drug has been 'largely mixed,' and it examines a range of ethical concerns—concluding these concerns are often legitimate but not conclusive reasons against prescribing it for weight loss. This source does not report on specific named phase 3 trials, HbA1c outcomes, or regulatory approval status.

Using it with other compounds

Check a stack
  • TesamorelinComplementary

    Worth caution

    Both reduce fat but by unrelated mechanisms — semaglutide via appetite/energy-intake reduction and tesamorelin via GH-driven lipolysis targeting visceral and liver fat. They can be complementary for body-composition goals, but growth hormone tends to raise blood glucose and lower insulin sensitivity, which works against semaglutide's glycemic benefit, so blood sugar should be monitored.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support lipolysis as a shared dimension: Semaglutide produces 'Weight loss / reduction in body weight and visceral fat' and carries the 'lipolysis' tag. Tesamorelin explicitly targets 'Reduction of visceral (abdominal) adipose tissue, Lipolysis' and 'Reduction of hepatic fat' with the 'lipolysis' tag. The proposed explanation correctly identifies that they achieve lipolysis through distinct mechanisms (semaglutide via appetite suppression/energy intake; tesamorelin via GH-axis/IGF-1 signaling), which justifies the 'complementary' relationship type. The caveat about potential glucose/insulin sensitivity interactions is reasonable given semaglutide's glucose-dependent insulin secretion pathway versus tesamorelin's GH effects, though this represents a potential limitation rather than contradicting the complementary relationship for lipolysis-focused goals.

    Shares lipolysis

  • SermorelinComplementary

    Worth caution

    Sermorelin raises endogenous GH/IGF-1 to promote lipolysis and lean mass, a different route to fat loss than semaglutide's appetite suppression. Potentially complementary for recomposition, but GH-axis stimulation can blunt insulin sensitivity, so anyone using semaglutide for glucose control should watch fasting glucose.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms include lipolysis as an approved tag and produce fat loss through distinct pathways: semaglutide via appetite suppression and metabolic effects through GLP-1 receptor signaling, and sermorelin via GH/IGF-1 axis stimulation. The mechanism descriptions support the claim that these represent different routes to a shared outcome (lipolysis/fat reduction), which justifies the 'complementary' relationship type with 'lipolysis' as a shared dimension. The caveat about GH potentially affecting insulin sensitivity is a reasonable mechanistic consideration based on the described pathways, though not explicitly detailed in the provided mechanisms.

    Shares lipolysis

  • TirzepatideSame mechanism

    Research does not support combining these

    Tirzepatide activates the very same GLP-1 receptor as semaglutide (plus the GIP receptor). Running both together is not additive in a useful way — you are hitting the same appetite/insulin pathway twice, which mostly stacks the side effects (nausea, vomiting, delayed gastric emptying, and risk of low blood sugar if combined with other glucose-lowering agents) rather than giving proportionally more benefit. These are alternatives, not a stack: pick one incretin agonist.

    Tier 2Supported by animal / early studies

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish a shared GLP-1 receptor target. Semaglutide is described as a GLP-1 receptor agonist, and tirzepatide is explicitly stated to activate the GLP-1 receptor (in addition to GIP receptor). Both mechanisms document appetite suppression/reduction as a direct effect. The explanation correctly identifies that tirzepatide activates 'the very same GLP-1 receptor as semaglutide' and that this shared pathway (appetite/insulin signaling via GLP-1R) would result in overlapping rather than additive effects. The proposed relationship of 'same_mechanism' with 'appetite_regulation' as the shared dimension is justified by the provided mechanism material showing both peptides target GLP-1R and both produce appetite-related effects through this pathway.

    Timing Do not co-administer; if switching between them, allow a washout and dose-titrate the new agent from a low dose.

    Shares appetite regulation

  • MOTS-cComplementary

    No documented conflict

    Both improve glucose handling and drive fat loss but by entirely different mechanisms: semaglutide is a GLP-1 receptor agonist acting on insulin/glucagon and appetite, while MOTS-c works intracellularly via AMPK and improved mitochondrial/glucose metabolism. Combining a central/hormonal metabolic driver with a cellular energy-sensing one is a rational complementary metabolic pairing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanisms clearly support a complementary relationship on the shared dimensions of mitochondrial_function and lipolysis. MOTS-c's mechanisms explicitly include AMPK activation, Keap1-Nrf2 antioxidant pathways, and mitochondrial-derived signaling (mitokine), directly supporting mitochondrial_function. Semaglutide's mechanisms include BNIP3-mediated mitochondrial signaling, also supporting mitochondrial_function. Both peptides demonstrate lipolysis effects: MOTS-c via white adipose tissue browning/thermogenesis and reduced fat mass; semaglutide via weight loss and visceral fat reduction. Critically, the mechanisms operate through distinct pathways—MOTS-c via intracellular AMPK/Keap1-Nrf2 and folate-cycle disruption, semaglutide via GLP-1 receptor agonism affecting insulin secretion, glucagon suppression, and appetite—which justifies the 'entirely different mechanisms' claim. The explanation that combining a central/hormonal metabolic driver (semaglutide) with a cellular energy-sensing one (MOTS-c) is rational is well-supported by the provided mechanism material. No contradictions are present.

    Shares mitochondrial function · lipolysis

  • AOD-9604Complementary

    May be complementary

    Semaglutide reduces body fat mainly by curbing appetite and improving glucose/insulin handling through the GLP-1 receptor, while AOD-9604 works peripherally to mobilize and oxidize stored fat. Different mechanisms aimed at the same weight/fat-loss goal, so they can complement each other.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms include lipolysis/fat loss as a documented effect. AOD-9604 directly stimulates lipolysis via beta3-AR and cAMP/PKA pathways (explicitly tagged 'lipolysis'). Semaglutide is also tagged 'lipolysis' and achieves weight loss/fat reduction, though primarily through appetite suppression and glucose control rather than direct lipolysis stimulation. The proposed relationship correctly identifies that they operate via distinct mechanisms (peripheral fat mobilization vs. central appetite/metabolic control) converging on the same outcome (fat loss). This represents a genuine complementary relationship on the shared dimension of lipolysis/fat reduction, supported by both peptides' documented effects and the mechanistic distinction described in the explanation.

    Shares lipolysis

  • MK-677Stack with caution

    Worth caution

    MK-677 increases appetite while semaglutide suppresses it — opposing effects on food intake. Some use GLP-1 agonists deliberately to offset MK-677's hunger, but the two also pull insulin sensitivity in different directions (MK-677 can raise glucose/reduce insulin sensitivity; semaglutide improves glycemic control), so glucose should be monitored.

    Tier 4Theoretical — not established
  • HumaninSame downstream effect

    Worth caution

    Both improve glucose handling and insulin sensitivity but by completely different upstream mechanisms — semaglutide is a GLP-1 receptor agonist boosting glucose-dependent insulin secretion and appetite suppression, whereas humanin is reported to improve insulin sensitivity via mitochondrial/IGF signaling. They converge on the same metabolic endpoint, which is worth monitoring if combined (watch glucose).

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    While both peptides have approved tags for 'mitochondrial_function' and 'mTOR_PI3K', the mechanism descriptions do not establish that they share these downstream pathways. For humanin, mitochondrial_function and mTOR_PI3K are explicitly documented (enhanced mitochondrial biogenesis, PI3K/Akt pathway). For semaglutide, the mechanisms show only BNIP3-mediated mitochondrial signaling in an animal cardiotoxicity model and PI3K/AKT in that same context—neither is presented as a primary or established pathway for semaglutide's glucose/metabolic effects. The explanation correctly identifies different upstream mechanisms (GLP-1 receptor vs. mitochondrial/IGF signaling) but does not demonstrate convergence on the same documented downstream pathways. The shared tags alone do not justify 'same_downstream' without explicit mechanistic overlap in the descriptions provided.

    Shares mitochondrial function · mTOR PI3K

  • Melanotan IISame downstream effect

    Worth caution

    Semaglutide's satiety effect works partly by driving hypothalamic POMC/melanocortin (MC4R) signaling, and Melanotan II is a direct MC4R agonist that also suppresses appetite. They converge on the same anorexigenic circuit, so combining them can compound appetite loss and nausea rather than add distinct benefit.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions provided do not establish that semaglutide drives hypothalamic POMC/melanocortin (MC4R) signaling. Semaglutide's description lists GLP-1 receptor targeting and effects on glucose-dependent insulin secretion, glucagon suppression, and PI3K/AKT pathway activation—but contains no mention of MC4R signaling or melanocortin pathway involvement. While both peptides produce appetite suppression (a shared effect), the mechanisms provided do not demonstrate they converge on the same downstream MC4R-mediated anorexigenic circuit. The proposed explanation requires mechanistic information about semaglutide's hypothalamic POMC/MC4R engagement that is absent from the provided material. Without explicit mechanism support for this convergence, the relationship cannot be confirmed as supported by the given descriptions.

    Shares appetite regulation

  • LinaclotideComplementary

    Worth caution

    GLP-1 agonists like semaglutide slow gastric emptying and commonly cause constipation, whereas linaclotide accelerates gut transit and softens stool. In practice linaclotide can counteract GLP-1-induced constipation, so the two have opposing effects on motility that can offset one another. Watch stool consistency: too much fluid secretion plus altered emptying can tip toward diarrhea or cramping.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed relationship claims the peptides have 'complementary' effects based on opposing impacts on gut motility (semaglutide slowing gastric emptying vs. linaclotide accelerating transit). However, the provided mechanism descriptions do not establish this relationship. Semaglutide's mechanism material lists 'Delayed gastric emptying' as an effect but provides no mechanistic detail about how this occurs or its relationship to constipation. Linaclotide's mechanisms clearly describe acceleration of intestinal/colonic transit and increased fluid secretion via GC-C/cGMP/CFTR pathways. While the explanation invokes real-world clinical observations about GLP-1-induced constipation and linaclotide's counteracting potential, these observations are not grounded in the provided mechanism descriptions themselves. The mechanisms do not explicitly connect semaglutide's delayed gastric emptying to constipation, nor do they establish a mechanistic basis for why linaclotide would specifically counteract GLP-1 effects. The relationship is plausible from external pharmacology knowledge but is not justified by the mechanism material provided.

    Timing Monitor bowel response; adjust linaclotide dose to GI symptoms.

  • Alpha-MSHSame downstream effect

    Worth caution

    GLP-1 receptor activation reduces appetite in part by stimulating hypothalamic POMC neurons that release alpha-MSH acting on MC4R; alpha-MSH is that same downstream satiety signal. The two therefore hit overlapping appetite-suppression machinery, so effects on food intake may be additive but are mechanistically redundant.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    While the proposed relationship describes a plausible biological mechanism (GLP-1 stimulating POMC neurons that release alpha-MSH), the provided mechanism descriptions do not establish this connection. Semaglutide's mechanism material describes GLP-1 receptor agonism and downstream pathways (glucose-dependent insulin secretion, glucagon suppression, PI3K/AKT, BNIP3-mediated mitochondrial signaling) but does not mention POMC neurons, hypothalamic signaling, or alpha-MSH. Alpha-MSH's mechanism material describes melanocortin receptor signaling and its direct effects but does not reference GLP-1 or describe it as a downstream consequence of GLP-1 activation. The explanation invokes a mechanistic relationship between the two peptides that is not supported by the provided mechanism descriptions, even though both peptides independently affect appetite suppression. To qualify as 'supported,' the mechanism material would need to explicitly describe the GLP-1→POMC→alpha-MSH pathway or similar direct mechanistic linkage.

    Shares appetite regulation

Safety and side effects

Common Side Effects

The most common adverse effects are mild-to-moderate, transient gastrointestinal symptoms: nausea, diarrhea, constipation, and vomiting. Across ten RCTs (14,550 participants, 7,830 on semaglutide), reported rates included nausea 2.05–19.95%, diarrhea 1.4–13%, vomiting ~5.97%, constipation ~6.91%, headaches ~7.92%, decreased appetite ~7%, and increased lipase ~6.5%; serious adverse events ranged 7–25.2%. In the East Asia obesity trial, GI disorders occurred in 59% (2.4 mg), 64% (1.7 mg), and 30% (placebo), mostly mild-to-moderate, with adverse-event-related discontinuation of 3% (semaglutide) versus 1% (placebo).

Serious Risks

  • Thyroid C-cell tumors: In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. Human relevance is undetermined; observed thyroid cancer incidence in treated patients was <1%, but definitive conclusions for thyroid and pancreatic cancer cannot be drawn due to low event rates.
  • Contraindication: Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Pancreatitis: Acute pancreatitis has been observed with GLP-1 receptor agonists including Wegovy.
  • Gallbladder/biliary disease: Acute gallbladder disease (cholelithiasis) has occurred in clinical trials.
  • Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. In monotherapy there is no hypoglycemia risk.
  • Diabetic retinopathy: Patients at risk of retinopathy deterioration should be carefully monitored, particularly if also on insulin.
  • MASH monitoring: In ESSENCE the hepatic safety profile was favorable (no discontinuations due to liver enzyme elevations), but clinicians are advised to monitor for rare but serious risks including acute kidney injury, gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and lean mass loss.

Other Considerations

  • 'Ozempic face': Rapid facial fat/volume depletion causing wrinkles and sagging skin has been described anecdotally, not established from controlled trials.
  • Anesthesia: Discontinuation prior to general anesthesia has been suggested due to delayed gastric emptying.
  • Eating disorders: There is insufficient evidence for use in eating disorders, and GLP-1As could potentially worsen ED pathology.

Overall Tolerability

Semaglutide is generally well tolerated with an overall favorable risk/benefit profile in type 2 diabetes. It has limited drug-drug interactions and its safety profile is similar to other GLP-1RAs, with no unexpected safety issues to date. In the cardiovascular outcomes trial, it was associated with fewer serious adverse events across all BMI categories, though trial product discontinuations increased as BMI class decreased.

Pregnancy

Semaglutide is not recommended during pregnancy, and weight loss offers no benefit during pregnancy. Because it has a half-life of roughly one week and takes about 4–5 weeks to clear after the last dose, it should be discontinued well in advance of a planned pregnancy. Anyone who could become pregnant should discuss contraception and timing of discontinuation with their clinician before starting or while using semaglutide.

Reconstitution and handling

Administration

Semaglutide is given by subcutaneous injection in the abdomen, thigh, or upper arm, once weekly on the same day each week, at any time of day, with or without meals—as an adjunct to diet and increased physical activity. Oral semaglutide (Rybelsus) is taken once daily; because bioavailability is low (~0.8%) and dependent on dosing conditions, it should be taken under fasting conditions (~30 minutes before other intake) with a small volume of water (≤120 mL). Longer post-dose fasting increases exposure, while larger water volumes decrease it.

Dosing (Wegovy example)

Wegovy is initiated at 0.25 mg once weekly for 4 weeks, then titrated every 4 weeks through available doses of 0.25, 0.5, 1, 1.7, and 2.4 mg. The recommended maintenance dose is 2.4 mg once weekly (or 1.7 mg if 2.4 mg is not tolerated) for most indications. For MASH, the maintenance dose is 2.4 mg (or 1.7 mg if not tolerated). Steady state is reached after 4–5 weeks. In clinical trials, SUSTAIN and PIONEER used 1.0 mg once-weekly subcutaneous and oral semaglutide for T2DM, while STEP used 2.4 mg once-weekly subcutaneous semaglutide for obesity.

Dose Adjustment

No dose adjustment is necessary in patients with upper gastrointestinal disease, renal impairment, or hepatic impairment, and none was needed in Chinese patients with type 2 diabetes. Semaglutide has been shown safe in adults and elderly patients with renal or hepatic disorders without dose modification, and has limited drug-drug interactions. For MASH, patient selection targets stage 2–3 fibrosis identified with non-invasive tests such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5).

Note: This information restates published clinical and regulatory data and is not dosing guidance.

Sources

Ordered by evidence quality — the strongest first.

  1. A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist | Request PDF(opens in a new tab)
    Tier 1Web · researchgate.net
  2. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  3. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials - PMC(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  4. Clinical Pharmacokinetics of semaglutide | DDDT | Dove Medical Press(opens in a new tab)
    Tier 1Web · dovepress.com
  5. Clinical Pharmacokinetics of Semaglutide: A Systematic Review(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  6. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. (5.1, 13.1) WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors. (4, 5.1) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙RECENT MAJOR CHANGES∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Indications and Usage (1) 08/2025 Dosage and Administration, Recommended Dosage Initiation and Escalation Schedule, Recommended Maintenance Dosage (2.2, 2.3) 08/2025 Warnings and Precaution, Acute Kidney Injury Due to Volume Depletion (5.5) 08/2025 Warning and Precautions, Severe Gastrointestinal Adverse Reactions, Pulmonary Aspiration During General Anesthesia or Deep Sedation (5.6, 5.11) 11/2024 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙INDICATIONS AND USAGE∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. (1) to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity. Adults with overweight in the presence of at least one weight related comorbid condition. (1) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. (1) The indication for MASH is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. (1) Limitations of Use Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. (1) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙DOSAGE AND ADMINISTRATION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals. (2.1) Inject subcutaneously in the abdomen, thigh, or upper arm. (2.1) In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment. (2.1) Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage. (2.2) For patients with MASH, the maintenance dosage of WEGOVY is 2.4 mg once weekly. If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly. (2.3) For all other indications except for MASH treatment, the maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly. (2.3)(opens in a new tab)
    Tier 1Web · accessdata.fda.gov
  7. Label: WEGOVY- semaglutide injection, solution(opens in a new tab)
    Tier 1Web · dailymed.nlm.nih.gov
  8. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist - PubMed(opens in a new tab)
    Tier 1Web · pubmed.ncbi.nlm.nih.gov
  9. Population Pharmacokinetics of Semaglutide for Type 2 Diabetes - PMC(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  10. Rybelsus, INN-semaglutide(opens in a new tab)
    Tier 1Web · ema.europa.eu
  11. Semaglutide - StatPearls - NCBI Bookshelf - NIH(opens in a new tab)
    Tier 1Web · ncbi.nlm.nih.gov
  12. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  13. Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects(opens in a new tab)
    Tier 1Web · d-nb.info
  14. Wegovy, INN-semaglutide(opens in a new tab)
    Tier 1Web · ema.europa.eu
  15. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  16. The Ethics of Ozempic and Wegovy.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  17. Semaglutide - StatPearls - NCBI Bookshelf - NIH(opens in a new tab)
    Tier 1Web · ncbi.nlm.nih.gov · 2024
  18. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  19. Clinical Pharmacokinetics of Semaglutide: A Systematic Review.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  20. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  21. Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  22. Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  23. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  24. Wegovy (semaglutide): a new weight loss drug for chronic weight management.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  25. Safety of Semaglutide.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  26. Semaglutide: First Global Approval.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  27. Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  28. As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  29. Semaglutide (Ozempic) for weight loss.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  30. Use of glucagon-like peptide-1 receptor agonists in eating disorder populations.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  31. Original Article(opens in a new tab)
    Tier 4Web · sciencehub.novonordisk.com